Fred D. Ledley is a physician-scientist, entrepreneur, and educator, who has authored >200 articles on topics ranging from molecular human biology and biotechnology, to STEM education, business, and bioethics. His work has contributed to emerging knowledge and policy related to human gene therapy, personalized medicine, and the translation of science for public value. He is currently Professor of Natural & Applied Sciences and Management, and Director of the Center for Integration of Science and Industry, at Bentley University. He served previously on the faculties of the Howard Hughes Medical Institute, Baylor College of Medicine, and Texas Children’s Hospital. He was a founder of several biotechnology companies, including GeneMedicine, where he served as Vice President Research & Development, and Varigenics, where he served as President & CEO. Dr. Ledley has a B.S. in physical science from the University of Maryland and a M.D. from Georgetown University School of Medicine, trained in Pediatrics and Genetics at Boston Children’s Hospital, and was an American Cancer Society post-doctoral fellow with Dr. David Baltimore at the Massachusetts Institute of Technology. He is the author of a novel, Sputnik’s Child.
Fred Ledley
![](https://www.ineteconomics.org/cpresources/userphotos/fledley/100/ledley-head-shot.jpg?x=pU4q5ScEi)
By this expert
Big Pharma Wants to Pocket the Profits From a COVID Treatment You Already Paid For
![](/uploads/featured/iStock-673436632.jpg)
Gilead’s shareholders want exorbitant profits from Remdesivir, even though it was the public that enabled its development.
The Fleming Myth and the Public Sector Contribution to Discovery and Development of New Cancer Drugs
![](/uploads/featured/Research-Lab-1.jpg)
Abstract, “basic science” research is essential to drug discovery. It is also largely funded by the public sector.
Taxpayer Investment Leads New Drug Discoveries
New research points to critical role of public funding in drug discoveries and development for the last decade